Spots Global Cancer Trial Database for 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

Official Title: 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

Study ID: NCT05850377

Conditions

High Grade Glioma

Glioma

Glioma, Malignant

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Photosensitizing Agents

Neoplasm Malignant

Brain Neoplasms, Adult, Malignant

Central Nervous System Neoplasms

Brain Tumor

Tumour, Residual

Interventions

5-Aminolevulinic Acid (5-ALA) Gliolan®

Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)

Study Description

Brief Summary: The goal of this observational study is to evaluate disease-free survival (DFS) in patients with malignant gliomas undergoing neurosurgical procedures using 5-aminolevulinic acid (5-ALA)-based photodynamic therapy

Detailed Description: The investigators are proposing a study that provides descriptive understanding of patients with High-Grade Gliomas in Ecuador. The primary objective of this pilot study is to lay the foundations for the development of a multicenter registry patients with malignant gliomas undergoing neurosurgical procedures using 5-aminolevulinic acid (5-ALA)-based photodynamic therapy, which will provide high-quality real data and serve as a basis for the application to future projects and elaboration of public policies in the medium and long term.